<DOC>
	<DOCNO>NCT01493440</DOCNO>
	<brief_summary>Atosiban , administer embryo transfer , improve implantation rate clinical pregnancy rate patient repeat implantation failure undergo IVF-ET ( in-vitro fertilization embryo transfer ) .</brief_summary>
	<brief_title>Atosiban Improves Implantation Pregnancy Rates Patients With Repeated Implantation Failure</brief_title>
	<detailed_description>Atosiban mixed oxytocin vasopressin V1A receptor antagonist.Combined antagonism oxytocin vasopressin V1A receptor reduce uterine contraction correspond decrease intrauterine production prostaglandin F2alpha improve uterine blood supply . These effect potential benefit implantation support IVF-ET cycle .</detailed_description>
	<mesh_term>Atosiban</mesh_term>
	<mesh_term>Vasotocin</mesh_term>
	<criteria>repeat implantation failure least 1 good quality embryo transfer uterine abnormality could compromise implantation process ( e.g . fibroid , endometrial polyp , bicornuate uterus , adhesion uterine cavity )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>atosiban</keyword>
	<keyword>clinical pregnancy</keyword>
	<keyword>implantation rate</keyword>
	<keyword>uterine contractility</keyword>
	<keyword>IVF-ET</keyword>
</DOC>